Literature DB >> 12388538

Ceramide signaling in fenretinide-induced endothelial cell apoptosis.

Anat Erdreich-Epstein1, Linda B Tran, Nina N Bowman, Hongtao Wang, Myles C Cabot, Donald L Durden, Jitka Vlckova, C Patrick Reynolds, Monique F Stins, Susan Groshen, Melissa Millard.   

Abstract

Stress stimuli can mediate apoptosis by generation of the lipid second messenger, ceramide. Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)). 4-HPR, a synthetic derivative of retinoic acid that induces ceramide in tumor cell lines, has been shown to have antiangiogenic effects, but the molecular mechanism of these is largely unknown. We report that 4-HPR was cytotoxic to endothelial cells (50% cytotoxicity at 2.4 microm, 90% at 5.36 microm) and induced a caspase-dependent endothelial apoptosis. 4-HPR (5 microm) increased ceramide levels in endothelial cells 5.3-fold, and the increase in ceramide was required to achieve the apoptotic effect of 4-HPR. The 4-HPR-induced increase in ceramide was suppressed by inhibitors of ceramide synthesis, fumonisin B(1), myriocin, and l-cycloserine, and 4-HPR transiently activated serine palmitoyltransferase, demonstrating that 4-HPR induced de novo ceramide synthesis. Sphingomyelin levels were not altered by 4-HPR, and desipramine had no effect on ceramide level, suggesting that sphingomyelinase did not contribute to the 4-HPR-induced ceramide increase. Finally, the pancaspase inhibitor, t-butyloxycarbonyl-aspartyl[O-methyl]-fluoromethyl ketone, suppressed 4-HPR-mediated apoptosis but not ceramide accumulation, suggesting that ceramide is upstream of caspases. Our results provide the first evidence that increased ceramide biosynthesis is required for 4-HPR-induced endothelial apoptosis and present a molecular mechanism for its antiangiogenic effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388538     DOI: 10.1074/jbc.M209962200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  The bioactive lipid 4-hydroxyphenyl retinamide inhibits flavivirus replication.

Authors:  Margot Carocci; Stephen M Hinshaw; Mary A Rodgers; Valerie A Villareal; Dominique J Burri; Rajendra Pilankatta; Natalya P Maharaj; Michaela U Gack; Eric J Stavale; Kelly L Warfield; Priscilla L Yang
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamide.

Authors:  Nadine Darwiche; Ghada Abou-Lteif; Tarek Najdi; Lina Kozhaya; Ahmad Abou Tayoun; Ahmad Abou Tayyoun; Ali Bazarbachi; Ghassan S Dbaibo
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

Review 3.  Cancer treatment strategies targeting sphingolipid metabolism.

Authors:  Babak Oskouian; Julie D Saba
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 4.  Ceramide synthases at the centre of sphingolipid metabolism and biology.

Authors:  Thomas D Mullen; Yusuf A Hannun; Lina M Obeid
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

5.  Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells.

Authors:  Xing-Zhong Wu; Li Zhang; Bi-Zhi Shi; Ping Hu
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

Review 6.  Dihydroceramides: From Bit Players to Lead Actors.

Authors:  Monowarul Mobin Siddique; Ying Li; Bhagirath Chaurasia; Vincent A Kaddai; Scott A Summers
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

Review 7.  Cardiovascular effects of sphingosine-1-phosphate and other sphingomyelin metabolites.

Authors:  Astrid E Alewijnse; Stephan L M Peters; Martin C Michel
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

8.  Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.

Authors:  Judith G Villablanca; Wendy B London; Arlene Naranjo; Patrick McGrady; Matthew M Ames; Joel M Reid; Renee M McGovern; Sarah A Buhrow; Hollie Jackson; Enno Stranzinger; Brenda J Kitchen; Paul M Sondel; Marguerite T Parisi; Barry Shulkin; Gregory A Yanik; Susan L Cohn; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

9.  CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit.

Authors:  Haruka Kamiyama; Katsura Kakoki; Sayuri Shigematsu; Mai Izumida; Yuka Yashima; Yuetsu Tanaka; Hideki Hayashi; Toshifumi Matsuyama; Hironori Sato; Naoki Yamamoto; Tetsuro Sano; Yoshihiro Shidoji; Yoshinao Kubo
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

10.  Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Authors:  Bryan J Schneider; Francis P Worden; Shirish M Gadgeel; Ralph E Parchment; Collette M Hodges; James Zwiebel; Rodney L Dunn; Antoinette J Wozniak; Michael J Kraut; Gregory P Kalemkerian
Journal:  Invest New Drugs       Date:  2009-02-19       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.